--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About OTLK20260220P0.5
Pharmaceutical
Outlook Therapeutics, Inc., was incorporated in New Jersey on January 5, 2010. The company is a biopharmaceutical company that is the first to obtain marketing authorization for ONS-5010/LYTENAVA (bevacizumab-gamma) ophthalmic preparations in the EU or EU, UK or UK for the treatment of wet age-related macular degeneration, or wet AMD.
